Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The company’s stock had lost 10.1% as of 2 p.m. ET, but was down as much as 12.5% earlier in the day. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite gained 1.1% on the day.
Merck’s stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly beat Wall Street’s revenue targets, weak guidance for 2025 disappointed investors.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
For Q4 2024, Merck reported global sales of $15.6 billion, up 7% year over year and narrowly beating expectations. The company delivered a net income of $3.74 billion, which although up from a $1.2 billion loss in Q4 2023, missed Wall Street’s expected $3.92 billion. For the full year, Merck reported $64.2 billion in revenue, up 7% from 2023.
The real disappointment came from the company’s guidance for 2025. It is forecasting at most $65.6 billion in sales for the coming year, well under the expected $67.1 billion.
Merck’s biggest moneymakers are its HPV vaccine, Gardasil, and its cancer drug, Keytruda. China is a critical market for Gardasil. Sales there have already been slowing and now new tariffs will further complicate the picture. In the longer term, Merck will have to adapt as its Keytruda patent is set to expire in 2028.
Merck must figure out how to right the ship and turn its Gardasil sales around if it is to succeed. There is hope for the drugmaker, however. Gardasil was recently approved for men and the company expects this to provide a much-needed boost.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $302,501!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,181!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $527,934!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of February 3, 2025
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]